IMT-009 was generally well tolerated as monotherapy and in combination with fruquintinib, demonstrating early signs of anti-tumor activity in heavily pretreated patients Translational findings suggest ...
IMT-009 is a fully human, Fc-attenuated IgG1 monoclonal antibody that binds to CD161 and blocks its interaction with its ligand, CLEC2D. Preclinical data confirm that CD161 blockade with IMT-009 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results